If you are experiencing a medical emergency, contact emergency services immediately: Emergency contacts and medical assistance
Crisis Scenario 1 — Erythrodermic Psoriasis
Erythrodermic psoriasis is the most severe and potentially life-threatening form of psoriasis, characterised by near-total body skin involvement (> 90% BSA) with intense erythema and scaling. It can develop from unstable plaque psoriasis — often triggered by abrupt withdrawal of systemic steroids, infection, or certain medications (lithium, beta-blockers, antimalarials).
Warning signs: - Rapid spread of redness and scaling to almost the entire body surface - Intense burning or itching across the whole skin - Fever and chills (temperature dysregulation — the skin can no longer regulate heat) - Rapid heart rate (compensatory for skin vasodilation and protein loss) - Swollen lymph nodes - Generalised malaise and confusion in severe cases
Medical risks: Erythrodermic psoriasis disrupts the skin barrier entirely. Complications include high-output cardiac failure, hypothermia or hyperthermia, severe dehydration, protein and electrolyte loss, and secondary skin infection. Mortality risk is real in severe cases.
What to do: Emergency room immediately. Do not attempt to manage this at home or wait for a dermatologist outpatient appointment. This is a medical emergency. Treatment involves hospitalisation, IV fluids, electrolyte correction, careful wound care, and systemic therapy (cyclosporine is often used for rapid disease control; biologic rescue is possible).
PMB coverage: Emergency hospitalisation for erythrodermic psoriasis qualifies as a PMB emergency benefit. Your scheme must cover emergency admission costs. A dermatologist shortfall may apply.
Crisis Scenario 2 — Acute Generalised Pustular Psoriasis (Von Zumbusch)
Generalised pustular psoriasis in the Von Zumbusch pattern is a dermatological emergency: widespread sterile pustules on erythematous skin, accompanied by high fever, systemic toxicity, neutrophilia, and severe malaise. This is a different disease from plaque psoriasis and is driven by IL-36 receptor activation.
Warning signs: - Sudden widespread eruption of sterile, yellow-white pustules on red, painful skin - High fever (> 39°C) and rigors - Severe systemic illness — appears very unwell - Can develop in known psoriasis patients after a trigger (infection, pregnancy, medication) or de novo
What to do: Emergency room immediately. IV fluids, systemic therapy (cyclosporine, acitretin, biologics — particularly IL-36 inhibitor spesolimab where available), and dermatologist-directed management. ICU-level care may be required in severe cases.
Crisis Scenario 3 — Biologic Access Denied: The Financial Crisis
Your dermatologist has recommended biologic therapy. Your scheme has declined the exceptional needs application. What now?
Let's focus on what we can control.
This is the most common "crisis" scenario for psoriasis patients — not a medical emergency, but a financial and bureaucratic one that can leave patients without effective treatment for months.
| Situation | What to Do |
|---|---|
| Scheme declined biologic — first application | Request formal written reasons. Submit appeal with full clinical motivation from dermatologist: PASI score, DLQI, documented csDMARD failures, photographs. |
| Scheme approves only anti-TNF (not IL-17/IL-23) | Anti-TNF (adalimumab biosimilar ~R5,000/month) is less effective for skin than anti-IL-17 agents, but may be a starting point. Re-motivate for IL-17 after clinical response data available. |
| No biologic funding at all | Consider manufacturer patient assistance programmes (PAPs). Some IL-17 and IL-23 manufacturers have access programmes for SA patients. Your dermatologist's rooms can advise. |
| PsA has developed | Switch to rheumatologist co-management. PsA may unlock CDL pathway, making biologic access mandatory (exceptional needs with CDL backing). |
| Cannot afford biologic OOP | Maximise methotrexate dose with close monitoring. Phototherapy as adjunct. Consider whether a scheme change would unlock better biologic access for next year. |
Note: Gap cover does not help with biologic access. Gap cover pays specialist shortfalls — it does not fund medications that your scheme has excluded from formulary. These are different problems with different solutions.
What Happens If You Are Hospitalised for Psoriasis
| Scenario | Gap Cover Helps? |
|---|---|
| Emergency admission: erythrodermic psoriasis | YES — dermatologist shortfall |
| Emergency admission: acute pustular psoriasis | YES — dermatologist shortfall |
| ICU admission (complications) | YES — intensivist + specialist shortfall |
| Cyclosporine infusion in hospital | YES — hospital day rate shortfall potential |
| Biologic initiation in hospital (IV loading dose) | YES — proceduralist shortfall |
| Outpatient biologic (SC self-injection) | NO — d2d funding issue, not gap issue |
In Hospital Right Now
- Call your scheme's 24-hour authorisation line within 48 hours of admission. For erythrodermic or pustular psoriasis, this is an emergency admission — PMB emergency benefit applies.
- Ask the treating dermatologist their billing rate. Dermatologists at private hospitals frequently bill above scheme rate.
- Notify your gap insurer with admission date, treating doctor name and practice number.
- Inform your scheme's managed care team that you are admitted and receiving systemic therapy — they may need to pre-authorise the medication.
Check your psoriasis cover — especially if biologic therapy is in your future. Run your AURA check